A phase 2 multi-center, open label long-term extension trial to assess the safety of oral UK-390 957 administered as required in adult men with premature ejaculation

Trial Profile

A phase 2 multi-center, open label long-term extension trial to assess the safety of oral UK-390 957 administered as required in adult men with premature ejaculation

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2012

At a glance

  • Drugs UK 390957 (Primary)
  • Indications Premature ejaculation
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top